HRA014210
Title:
Osimertinib with or without savolitinib as first-line treatment for MET-aberrant, EGFR-mutant NSCLC: randomized phase 2 trial (FLOWERS)
Release date:
2025-10-28
Description:
Poor response to EGFR inhibitor alone is seen in advanced non-small cell lung cancer with EGFR mutations and de novo MET aberrations. This Phase 2 randomized trial shows promising antitumor activity and good safety in such patients treated with first-line osimertinib plus savolitinib.
Data Accessibility:   
Open access
BioProject:
Study type:
Disease Study
Disease name:
non-small cell lung carcinoma
Dataset Download
MetaData:
Individuals & samples
Files
Submitter:   Yang Jin-Ji / yangjinji@gdph.org.cn
Organization:   Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, 510080, China
Submission date:   2025-10-28